Clinical trials: Bortezomib
Chronic Myeloid Leukemia (CML), Pancreatic Ca
Natural Killer Cells and Bortezomib to Treat Cancer
Natural killer (NK) cells are white blood cells that have a limited ability to kill cancer cells. This ability might be enhanced if they are given 24 hours after an injection of the drug bortezomib.
- Conditions
- Chronic Myeloid Leukemia (CML), Pancreatic Ca, Colon/Rectal Ca, Multiple Myeloma
- Trial name
- NCT00720785
- Testing
- Bortezomib, NK cells
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Lymphoproliferative Disorder, HHV-8
Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity
This study will gain information about a rare disorder called KSHV-associated multicentric Castleman's disease (MCD). KSHV, a virus, causes several kinds of cancer, including some forms of MCD.
- Conditions
- Lymphoproliferative Disorder, HHV-8, Malignancy, HIV
- Trial name
- NCT00092222
- Testing
- Etoposide, Interferon-alpha, Rituximab
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- National Cancer Institute (NCI)
Acute Myeloid Leukemia, TP53
Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML)
This is a Phase I/II study evaluating safety and efficacy of proteasome inhibitor (bortezomib) in combination with CPX-351 (liposomal daunorubicin and cytarabine) for the treatment of newly-diagnosed TP53-mutated acute myeloid…
- Trial name
- NCT07008638
- Testing
- Bortezomib, CPX-351
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Newly Diagnosed Multiple Myeloma (NDMM)
Less Doses of Daratumumab Are Adequate to Achieve Response in Newly Diagnosed Multiple Myeloma
The goal of this clinical trial is to evaluate whether a modified (less frequent) dosing schedule of daratumumab, when added to standard VRd therapy, can be an effective induction regimen for treating newly diagnosed multiple…
- Trial name
- NCT07891923
- Testing
- Daratumumab (Intravenously) with VRd (Bortezomib, Lenalidomide, and Dexamethasone)
- Where
- 2 sites in India
- Volunteers
- 52 people
- Sponsor
- Tata Memorial Centre
Unspecified Adult Solid Tumor, Protocol Specific
Bortezomib and Topotecan Hydrochloride in Treating Patients With Advanced Solid Tumors
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00541359
- Testing
- bortezomib, topotecan hydrochloride, immunohistochemistry staining method
- Where
- 2 sites in United States
- Volunteers
- 54 people
- Sponsor
- City of Hope Medical Center
Autologous Hematopoietic Stem Cell Transplant Recipient, Loss of Chromosome 17p
Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving chemotherapy drugs, such as fludarabine phosphate and melphalan, and total marrow irradiation before a donor…
- Conditions
- Autologous Hematopoietic Stem Cell Transplant Recipient, Loss of Chromosome 17p, Plasma Cell Leukemia, Recurrent Plasma Cell Myeloma
- Trial name
- NCT01163357
- Testing
- bortezomib, fludarabine phosphate, melphalan
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- City of Hope Medical Center
Plasma Cell Leukemia
Daratumumab, Bortezomib, Dexamethasone, Pegylated Liposomal Doxorubicin Hydrochloride, and Lenalidomide in Treating Participants With Plasma Cell Leukemia
This phase I trial studies side effects of daratumumab, bortezomib, dexamethasone, pegylated liposomal doxorubicin hydrochloride, and lenalidomide in treating participants with plasma cell leukemia.
- Trial name
- NCT03591744
- Testing
- Bortezomib, Daratumumab, Dexamethasone
- Where
- 5 sites in United States
- Sponsor
- City of Hope Medical Center
Multiple Myeloma (MM)
Comparing Bispecific Antibody Treatment to Autologous Stem Cell Transplant for Newly Diagnosed, Standard Risk Multiple Myeloma
This phase II/III trial compares the usual treatment (daratumumab and hyaluronidase, lenalidomide, bortezomib and dexamethasone [DaraRVd] regimen followed by autologous stem cell transplant [ASCT] followed by maintenance therapy)…
- Trial name
- NCT07887984
- Testing
- Daratumumab and Recombinant Human Hyaluronidase, Lenalidomide, Bortezomib
- Volunteers
- 920 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Adult T Acute Lymphoblastic Leukemia, Ann Arbor Stage II Adult Lymphoblastic Lymphoma
Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma
This randomized phase III trial compares how well combination chemotherapy works when given with or without bortezomib in treating patients with newly diagnosed T-cell acute lymphoblastic leukemia or stage II-IV T-cell…
- Conditions
- Adult T Acute Lymphoblastic Leukemia, Ann Arbor Stage II Adult Lymphoblastic Lymphoma, Ann Arbor Stage II Childhood Lymphoblastic Lymphoma, Ann Arbor Stage III Adult Lymphoblastic Lymphoma
- Trial name
- NCT02112916
- Testing
- Bortezomib, Cyclophosphamide, Cytarabine
- Where
- 212 sites in United States, Australia and 2 more
- Volunteers
- 847 people
- Sponsor
- National Cancer Institute (NCI)
Relapsed and/or Refractory Multiple Myeloma (RRMM)
A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
This study is researching a drug called linvoseltamab (also called "study drug") either given alone or in combination with another anti-myeloma drug called carfilzomib, compared to several standard treatments for progressive…
- Trial name
- LINKER-MM5 (NCT07222761)
- Testing
- Linvoseltamab, Carfilzomib, Daratumumab
- Where
- 44 sites in United States, Australia and 5 more
- Volunteers
- 915 people
- Sponsor
- Regeneron Pharmaceuticals
Newly Diagnosed Multiple Myeloma
A Trial to Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Standard of Care in Newly Diagnosed Multiple Myeloma
The goal of this clinical study iMMagine-4 is to compare and assess the safety and effectiveness of anitocabtagene autoleucel versus standard of care therapy (SOCT) in participants with newly diagnosed multiple myeloma (NDMM) who…
- Trial name
- iMMagine-4 (NCT07887672)
- Testing
- Anitocabtagene autoleucel, Daratumumab, Bortezomib
- Volunteers
- 600 people
- Sponsor
- Kite, A Gilead Company
Multiple Myeloma
Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in TIE Newly Diagnosed MM Patients
An unrandomized phase 2 study of selinexor in combination with lenalidomide/ bortezomib and dexamethasone to newly diagnosed, transplant in-eligible symptomatic multiple myeloma patients in a multicenter international set-up…
- Trial name
- SABLe (NCT04717700)
- Testing
- Selinexor 20 MG Oral Tablet, Bortezomib Injection, Lenalidomide capsule
- Where
- 11 sites in Denmark, Estonia and 1 more
- Volunteers
- 50 people
- Sponsor
- Ida Bruun Kristensen
Plasma Cell Myeloma
Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study
This phase I/II trial studies the side effects and best dose of iberdomide and how well it works in combination with daratumumab, bortezomib, and dexamethasone in treating patients with newly diagnosed multiple myeloma.
- Trial name
- NCT05392946
- Testing
- Bortezomib, Daratumumab, Dexamethasone
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Mayo Clinic
Primary Heart Transplant, Heart Transplantation
Safety and Efficacy of Desensitization Therapy in Sensitized Participants Awaiting Heart Transplantation
The primary objective is to evaluate the efficacy of desensitization therapy, which includes VELCADE® (bortezomib) and plasmapheresis, on select sensitized patients awaiting heart transplantation.
- Conditions
- Primary Heart Transplant, Heart Transplantation, Heart Transplant
- Trial name
- NCT01769443
- Testing
- bortezomib, plasmapheresis
- Where
- 14 sites in United States
- Volunteers
- 2 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Solid Tumor, Urethral Cancer
Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors
The goal of this clinical research study is to find the highest tolerable dose of Gemzar® (gemcitabine) and Adriamycin® (doxorubicin) that can be given together with Velcade® (bortezomib) in patients with urothelial cancer or…
- Trial name
- NCT00479128
- Testing
- Bortezomib, Gemcitabine, Doxorubicin
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- M.D. Anderson Cancer Center
Multiple Myeloma
D2 - Isa-Iber-VD Induction, Followed by Risk & Response Adapted Consolidation & Maintenance, in Transplant-Eligible NDMM
The purpose of the study is to determine the best treatment approach based on the risk profile of the cancer cells and on how the disease responds to treatment.
- Trial name
- NCT07624513
- Testing
- Isatuximab, Iberdomide, Bortezomib (B)
- Where
- 3 sites in United States
- Volunteers
- 720 people
- Sponsor
- Dana-Farber Cancer Institute
Newly Diagnosed Multiple Myeloma
Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM
This is a single center, open-label, phase 2 study in elderly (age ≥ 70) subjects with newly diagnosed multiple myeloma who are transplant ineligible.
- Trial name
- NCT04052880
- Testing
- Daratumumab, Bortezomib, Lenalidomide
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Larysa Sanchez
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
This phase II trial studies how well daratumumab, bortezomib, and dexamethasone followed by daratumumab, ixazomib, and dexamethasone in treating patients with multiple myeloma that has come back (relapsed) or does not response to…
- Trial name
- NCT03763162
- Testing
- Bortezomib, Daratumumab, Dexamethasone
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- M.D. Anderson Cancer Center
Multiple Myeloma
A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned
The main purpose of this study is to see how well a new treatment ramantamig-D works compared to standard treatments that is either DVRd or DRd on progression-free survival (PFS; time until a participant's disease worsens) and…
- Trial name
- TRIlogy-7 (NCT07665450)
- Testing
- Ramantamig, Daratumumab, Lenalidomide
- Where
- 30 sites in France, Greece and 7 more
- Volunteers
- 1,000 people
- Sponsor
- Janssen Research & Development, LLC
Plasma Cell Myeloma
Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
This randomized phase III trial studies bortezomib, lenalidomide, and dexamethasone to see how well they work compared to carfilzomib, lenalidomide, and dexamethasone in treating patients with newly diagnosed multiple myeloma.
- Trial name
- NCT01863550
- Testing
- Bortezomib, Carfilzomib, Dexamethasone
- Where
- 920 sites in United States, Puerto Rico
- Volunteers
- 1,087 people
- Sponsor
- ECOG-ACRIN Cancer Research Group